Bank of America’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.4M | Sell |
413,411
-322,529
| -44% | -$16.7M | ﹤0.01% | 2240 |
|
|
2026
Q1 | $35.4M | Buy |
735,940
+506,576
| +221% | +$22.4M | ﹤0.01% | 1888 |
|
|
2025
Q4 | $9.46M | Sell |
229,364
-266,119
| -54% | -$10.7M | ﹤0.01% | 2899 |
|
|
2025
Q3 | $19.2M | Buy |
495,483
+222,854
| +82% | +$7.24M | ﹤0.01% | 2655 |
|
|
2025
Q2 | $7.54M | Buy |
272,629
+32,982
| +14% | +$840K | ﹤0.01% | 3485 |
|
|
2025
Q1 | $5.32M | Buy |
239,647
+23,875
| +11% | +$491K | ﹤0.01% | 3739 |
|
|
2024
Q4 | $4.27M | Buy |
215,772
+4,654
| +2% | +$106K | ﹤0.01% | 3739 |
|
|
2024
Q3 | $5.28M | Sell |
211,118
-3,729
| -2% | -$90.8K | ﹤0.01% | 3692 |
|
|
2024
Q2 | $4.01M | Buy |
214,847
+2,342
| +1% | +$43.9K | ﹤0.01% | 3829 |
|
|
2024
Q1 | $4.19M | Buy |
212,505
+161,962
| +320% | +$3.16M | ﹤0.01% | 3776 |
|
|
2023
Q4 | $887K | Sell |
50,543
-62,016
| -55% | -$1.02M | ﹤0.01% | 5073 |
|
|
2023
Q3 | $1.96M | Buy |
112,559
+20,325
| +22% | +$342K | ﹤0.01% | 4260 |
|
|
2023
Q2 | $1.3M | Sell |
92,234
-96,785
| -51% | -$1.3M | ﹤0.01% | 4576 |
|
|
2023
Q1 | $2.03M | Buy |
189,019
+34,573
| +22% | +$455K | ﹤0.01% | 4336 |
|
|
2022
Q4 | $2.31M | Buy |
154,446
+128,298
| +491% | +$1.87M | ﹤0.01% | 4116 |
|
|
2022
Q3 | $336K | Buy |
26,148
+579
| +2% | +$6.6K | ﹤0.01% | 5665 |
|
|
2022
Q2 | $247K | Sell |
25,569
-6,493
| -20% | -$60.6K | ﹤0.01% | 5937 |
|
|
2022
Q1 | $319K | Sell |
32,062
-99,520
| -76% | -$1.05M | ﹤0.01% | 6142 |
|
|
2021
Q4 | $1.55M | Buy |
131,582
+91,030
| +224% | +$1.12M | ﹤0.01% | 4813 |
|
|
2021
Q3 | $462K | Buy |
40,552
+6,532
| +19% | +$85.1K | ﹤0.01% | 5716 |
|
|
2021
Q2 | $474K | Sell |
34,020
-24,852
| -42% | -$378K | ﹤0.01% | 5477 |
|
|
2021
Q1 | $1.09M | Buy |
58,872
+32,720
| +125% | +$669K | ﹤0.01% | 4749 |
|
|
2020
Q4 | $462K | Sell |
26,152
-245,052
| -90% | -$4.3M | ﹤0.01% | 5065 |
|
|
2020
Q3 | $4.16M | Buy |
271,204
+10,623
| +4% | +$199K | ﹤0.01% | 3085 |
|
|
2020
Q2 | $6.64M | Buy |
260,581
+92,390
| +55% | +$1.93M | ﹤0.01% | 2595 |
|
|
2020
Q1 | $2.6M | Buy |
168,191
+12,686
| +8% | +$198K | ﹤0.01% | 3280 |
|
|
2019
Q4 | $1.72M | Buy |
155,505
+19,993
| +15% | +$174K | ﹤0.01% | 4118 |
|
|
2019
Q3 | $1.15M | Buy |
135,512
+126,569
| +1,415% | +$1.4M | ﹤0.01% | 4454 |
|
|
2019
Q2 | $121K | Buy |
8,943
+4,854
| +119% | +$75.3K | ﹤0.01% | 5907 |
|
|
2019
Q1 | $74K | Sell |
4,089
-7,542
| -65% | -$146K | ﹤0.01% | 6028 |
|
|
2018
Q4 | $327K | Buy |
11,631
+10,594
| +1,022% | +$221K | ﹤0.01% | 5203 |
|
|
2018
Q3 | $27K | Buy |
+1,037
| New | +$20.2K | ﹤0.01% | 6412 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Bank of America's KNSA Position: Q2 2026 in Review
Bank of America reduced its Kiniksa Pharmaceuticals (KNSA) stake by 44% in Q2 2026, selling an estimated $16.7M and leaving 413,411 shares worth $26.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2240.
Bank of America first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. The position peaked at $35.4M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Bank of America held 413,411 shares of Kiniksa Pharmaceuticals worth $26.4M as of Q2 2026.
- Bank of America sold 322,529 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $16.7M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2240 holding.
- Bank of America first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Bank of America's Kiniksa Pharmaceuticals position peaked at $35.4M in Q1 2026.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.